C57BL/6JCya-Cdkn2aem1flox/Cya
Common Name:
Cdkn2a-flox
Product ID:
S-CKO-01681
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Cdkn2a-flox
Strain ID
CKOCMP-12578-Cdkn2a-B6J-VA
Gene Name
Product ID
S-CKO-01681
Gene Alias
ARF-INK4a; Arf; INK4a-ARF; Ink4a/Arf; MTS1; Pctr1; p16; p16(INK4a); p16INK4a; p19<ARF>; p19ARF
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
4
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Cdkn2aem1flox/Cya mice (Catalog S-CKO-01681) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000060501
NCBI RefSeq
NM_001040654
Target Region
Exon 1
Size of Effective Region
~1.5 kb
Detailed Document
Overview of Gene Research
Cdkn2a, encoding p16 and p14, is a crucial tumor suppressor gene [1,2]. It is involved in cell cycle regulation, as p16 inhibits CDK4/6, thus controlling cell proliferation. Its loss is linked to tumor progression, making it of great biological importance in cancer research [1].
Loss of Cdkn2a is a frequent driver of melanoma progression. Pharmacological inhibition of p16 targets CDK4/6, which is a potential therapeutic strategy. Other approaches include exploiting cell cycle deregulation, targeting metabolic rewiring, epigenetically restoring expression, acting on co-deleted gene dependencies, or modulating immune responses [1]. Additionally, CDKN2A is the most common homozygously deleted gene in all human cancers. Tumors often codelete the nearby gene MTAP, creating a dependency on PRMT5, and MTA-cooperative PRMT5 inhibitors show early efficacy in treating CDKN2A/MTAP-deleted cancers [2].
In conclusion, Cdkn2a is a key tumor suppressor gene, with its loss significantly contributing to cancer development, especially melanoma. Research on Cdkn2a-related therapeutic strategies offers potential new avenues for precision medicine in melanoma and understanding the treatment of CDKN2A/MTAP-deleted cancers [1,2].
References：
1. Kreuger, Inger Z M, Slieker, Roderick C, van Groningen, Tim, van Doorn, Remco. 2022. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. In The Journal of investigative dermatology, 143, 18-25.e1. doi:10.1016/j.jid.2022.07.016. https://pubmed.ncbi.nlm.nih.gov/36123181/
2. Mulvaney, Kathleen M. . Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers. In Cancer discovery, 13, 2310-2312. doi:10.1158/2159-8290.CD-23-0951. https://pubmed.ncbi.nlm.nih.gov/37909092/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen